News

hemotune raises CHF 7.25 million Series B1 funding

Hemotune, EIT Health Start-up Rescue Instrument winner, has raised CHF 7.25 million Series B1 funding for the development of their disruptive blood purification platform.

Hemotune develops the HemoSystem, a revolutionary medical device for blood purification that combines cutting-edge scientific results from biomedicine and nanotechnology. The primary applications of the technology are sepsis and septic shock which is underserved global health issue leading to around 11 million deaths every year and being one of the most expensive conditions. It mixes nanoengineered magnetic beads directly with patients’ blood in a dialysis-like machine where they bind to selected targets. While the blood flows through a magnetic filter, beads and bound targets are highly efficiently removed before it is recirculated to the patient’s body.

The current investment, led by OCCIDENT with the participation of all previous investors including Zürcher Kantonalbank and joined by the new investors HEMEX, VP Venture Partners as well as a global family office and private individuals, will allow hemotune to complete the preclinical development of HemoSystem and prepare a clinical trial in hemotune’s lead indication.

“We are very proud of our achievements in the past years, bringing the technology from a lab concept to a medical device soon to be used to the benefit of patients and building a great network of clinicians and immunologists. We are happy that all previous investors participated in the round and are welcoming the new investors on our journey to disrupt blood purification and sepsis treatment.” – says Lukas Langenegger, CEO and co-founder of hemotune AG.